Chardan Capital Forecasts MeiraGTx FY2026 Earnings

MeiraGTx Holdings plc (NASDAQ:MGTX - Free Report) - Research analysts at Chardan Capital issued their FY2026 earnings per share (EPS) estimates for MeiraGTx in a research report issued on Monday, March 24th. Chardan Capital analyst D. Gataulin forecasts that the company will earn ($1.09) per share for the year. Chardan Capital currently has a "Buy" rating and a $36.00 target price on the stock. The consensus estimate for MeiraGTx's current full-year earnings is ($1.48) per share.

MeiraGTx (NASDAQ:MGTX - Get Free Report) last issued its quarterly earnings data on Thursday, March 13th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.02). The business had revenue of $21.39 million for the quarter, compared to analysts' expectations of $1.50 million. MeiraGTx had a negative return on equity of 146.38% and a negative net margin of 633.05%.

Separately, Royal Bank of Canada increased their price objective on MeiraGTx from $11.00 to $13.00 and gave the company an "outperform" rating in a research report on Monday, March 17th.

MeiraGTx Price Performance

MGTX stock traded down $0.51 during midday trading on Thursday, reaching $6.82. The company had a trading volume of 266,778 shares, compared to its average volume of 283,928. The firm has a 50-day moving average price of $6.83 and a 200-day moving average price of $6.08. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.34 and a quick ratio of 2.34. The company has a market capitalization of $537.79 million, a P/E ratio of -5.66, a P/E/G ratio of 0.37 and a beta of 1.23. MeiraGTx has a 1 year low of $3.85 and a 1 year high of $8.75.

Remove Ads

Insiders Place Their Bets

In other news, CFO Richard Giroux sold 24,000 shares of the company's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $6.29, for a total transaction of $150,960.00. Following the completion of the transaction, the chief financial officer now directly owns 849,947 shares of the company's stock, valued at approximately $5,346,166.63. This represents a 2.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Alexandria Forbes sold 35,839 shares of the business's stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $6.47, for a total value of $231,878.33. Following the transaction, the chief executive officer now owns 1,395,102 shares in the company, valued at approximately $9,026,309.94. This represents a 2.50 % decrease in their position. The disclosure for this sale can be found here. 8.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Sanofi bought a new stake in shares of MeiraGTx during the 4th quarter valued at about $74,284,000. Woodline Partners LP bought a new stake in MeiraGTx during the 4th quarter valued at approximately $9,349,000. Knoll Capital Management LLC purchased a new position in shares of MeiraGTx during the 3rd quarter worth approximately $5,212,000. Erste Asset Management GmbH bought a new position in shares of MeiraGTx in the 3rd quarter worth approximately $2,795,000. Finally, Garden State Investment Advisory Services LLC purchased a new position in shares of MeiraGTx in the 3rd quarter valued at approximately $1,636,000. 67.48% of the stock is owned by hedge funds and other institutional investors.

MeiraGTx Company Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.